Jiangsu Jiejie Microelectronics (300623.SZ) forecasts a year-on-year net profit increase of 100% to 130%, with an expected annual net profit of 4.38 billion to 5.04 billion yuan.
Jiejie Microelectronics (300623.SZ) discloses its performance forecast for fiscal year 2024, with the company expecting its net profit attributable to shareholders of the listed company to...
Jiangsu Jiejie Microelectronics (300623.SZ) disclosed its performance forecast for 2024. The company expects a net profit attributable to shareholders of the listed company of 438 million to 504 million yuan, a year-on-year increase of 100% to 130%; after deducting non-recurring gains and losses, the net profit is expected to be 388 million to 449 million yuan, a year-on-year increase of 90% to 120%.
Related Articles
CONCORD NE (00182) spent 74,000 Hong Kong dollars to buy back 300,000 shares on March 31st.
WISDOMCOME GP (08079): Li Qinhui resigns as independent non-executive director.
CSPC PHARMA (01093): Anetumab ravtansine in combination with doxorubicin (albumin-bound) as neoadjuvant therapy achieves primary endpoint in phase III study for HER2+ breast cancer.
CONCORD NE (00182) spent 74,000 Hong Kong dollars to buy back 300,000 shares on March 31st.
WISDOMCOME GP (08079): Li Qinhui resigns as independent non-executive director.
CSPC PHARMA (01093): Anetumab ravtansine in combination with doxorubicin (albumin-bound) as neoadjuvant therapy achieves primary endpoint in phase III study for HER2+ breast cancer.
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026
